These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38040319)

  • 1. Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: A multicentre retrospective propensity score-matched study.
    Wang SH; Yang KY; Sheu CC; Lin YC; Chan MC; Feng JY; Chen CM; Chen CY; Zheng ZR; Chou YC; Peng CK;
    Int J Antimicrob Agents; 2024 Jan; 63(1):107044. PubMed ID: 38040319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
    Zhang Y; Xu G; Miao F; Huang W; Wang H; Wang X
    Front Public Health; 2023; 11():1282413. PubMed ID: 38098829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
    Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
    Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptations of carbapenem resistant
    Sharma S; Das A; Banerjee T; Barman H; Yadav G; Kumar A
    J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33739918
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia.
    Qiao L; Zuo W; Yang Y; Liu X; Wang Q; Yu J; Wu J; Xu T; Jiang J; Zhang B; Long Y
    Int J Antimicrob Agents; 2023 Aug; 62(2):106880. PubMed ID: 37301311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence, presentation and outcome of colistin susceptible-only Acinetobacter Baumannii-associated pneumonia in intensive care unit: a multicenter observational study.
    Wang SH; Yang KY; Sheu CC; Lin YC; Chan MC; Feng JY; Chen CM; Chen CY; Zheng ZR; Chou YC; Peng CK
    Sci Rep; 2023 Jan; 13(1):140. PubMed ID: 36599842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk factors and resistance patterns of invasive
    Ge YL; Shan QW; Qiu Y; Zhou SP; Cheng YB; Wang F; Yang JW; Wan CM; Zhu Y; Xu Y; Chen MX; Lin DJ; Zhu CH; Zeng M
    Zhonghua Er Ke Za Zhi; 2022 Aug; 60(8):762-768. PubMed ID: 35922185
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: a case control study.
    Chusri S; Silpapojakul K; McNeil E; Singkhamanan K; Chongsuvivatwong V
    J Infect Chemother; 2015 Feb; 21(2):90-5. PubMed ID: 25454216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
    Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
    Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
    Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
    Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
    Esterly JS; Griffith M; Qi C; Malczynski M; Postelnick MJ; Scheetz MH
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4844-9. PubMed ID: 21825287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
    Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
    Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
    [No Abstract]   [Full Text] [Related]  

  • 14. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study.
    Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T
    J Infect Public Health; 2023 Aug; 16(8):1249-1255. PubMed ID: 37295057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients.
    Ogutlu A; Guclu E; Karabay O; Utku AC; Tuna N; Yahyaoglu M
    Ann Clin Microbiol Antimicrob; 2014 Jan; 13():7. PubMed ID: 24405720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study.
    Chen CY; Yang KY; Peng CK; Sheu CC; Chan MC; Feng JY; Wang SH; Chen CM; Zheng ZR; Liang SJ; Lin YC;
    Sci Rep; 2022 May; 12(1):7501. PubMed ID: 35525867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Risk Factors for Healthcare-Associated Infections Caused by Carbapenem-Resistant
    Sultan AM; Seliem WA
    Sultan Qaboos Univ Med J; 2018 Feb; 18(1):e75-e80. PubMed ID: 29666685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
    Zhang TQ; Dong L; Wang ZY; Li HY
    Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in
    Liu Y; Wang Q; Zhao C; Chen H; Li H; Wang H; Cares Network OBOT
    J Med Microbiol; 2020 Jul; 69(7):949-959. PubMed ID: 32584215
    [No Abstract]   [Full Text] [Related]  

  • 20. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea.
    Seok H; Choi WS; Lee S; Moon C; Park DW; Song JY; Cheong HJ; Kim J; Kim JY; Park MN; Kim YR; Lee HJ; Kim B; Pai H; Jo YM; Kim JH; Sohn JW
    J Glob Antimicrob Resist; 2021 Mar; 24():429-439. PubMed ID: 33571708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.